Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study

• Hoofdauteurs: Jan Lewis Brandes (Auteur), Suzanne Klise (Auteur), John H Krege (Auteur), Michael Case (Auteur), Rashna Khanna (Auteur), Raghavendra Vasudeva (Auteur), Joel Raskin (Auteur), David Kudrow (Auteur)
• Formaat: Boek
• Gepubliceerd in: SAGE Publishing, 2020-09-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

GLADIATOR was a prospective, randomized, open-label, phase 3 study of lasmiditan 100 mg or 200 mg dosed intermittently for up to 1 year in patients with episodic migraine. Most patients had completed one of two single-attack studies before participation. A total of 2030 patients received ≥1 lasmidit...